Author:
Yoshida Yuichi,Shibata Hirotaka
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Miao Q, Chang G, Shen L, Chen Y, Li Q. Comment on: Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism. Hypertens Res. 2024;in press.
2. Yoshida Y, Fujiwara M, Kinoshita M, Sada K, Miyamoto S, Ozeki Y, et al. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism. Hypertens Res. 2024;47:157–67.
3. Ho WY, Hsiao CC, Wu PH, Chen JY, Tu YK, Wu VC, et al. Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis. Ther Adv Chronic Dis. 2024;15:20406223241239775.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl J Med. 1999;341:709–17.
5. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl J Med. 2011;364:11–21.